Form 4: Theravance Biopharma CFO Aziz Sawaf Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Aziz Sawaf, CFO of Theravance Biopharma, disposed of 8,635 ordinary shares to cover tax obligations related to vesting restricted stock units.
Summary
- On August 20, 2024, Aziz Sawaf, the SVP & Chief Financial Officer of Theravance Biopharma, Inc. [TBPH], disposed of 8,635 ordinary shares.
- The shares were disposed of to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was executed at a price of $8.22 per share.
- Following the transaction, Sawaf directly owns 321,366 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an insider transaction for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade in their company's stock. This provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of the share disposal transaction. |
| 08/22/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.